文献速递心脑血管急症呼吸衰竭与机械通气

阿哌沙班与利伐沙班治疗急性静脉血栓栓塞症的出血风险比较

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
PubMed 文献 · N Engl J Med · 2026-01-01
一句话结论急性静脉血栓栓塞症患者3个月治疗期内,阿哌沙班较利伐沙班显著降低临床相关出血风险(3.3% vs 7.1%,RR 0.46)。

该国际、前瞻性、随机、开放标签、盲法终点试验将2760例急性症状性肺栓塞或近端深静脉血栓患者按1:1随机分配至阿哌沙班组(1370例)或利伐沙班组(1390例),治疗3个月。阿哌沙班方案为10 mg每日两次×7天,随后5 mg每日两次;利伐沙班方案为15 mg每日两次×21天,随后20 mg每日一次。主要终点为3个月治疗期内依据国际血栓与止血学会定义的临床相关出血(大出血或临床相关非大出血复合终点),阿哌沙班组44/1345例(3.3%) vs 利伐沙班组96/1355例(7.1%)(相对风险0.46;95%CI 0.33–0.65;P<0.001)。全因死亡阿哌沙班组1例(0.1%) vs 利伐沙班组4例(0.3%)(相对风险0.25;95%CI 0.03–2.26)。

要点

  • 急性症状性肺栓塞或近端深静脉血栓患者,阿哌沙班3个月临床相关出血3.3%(44/1345) vs 利伐沙班7.1%(96/1355),相对风险0.46(95%CI 0.33–0.65;P<0.001)。
  • 阿哌沙班方案:10 mg每日两次×7天,随后5 mg每日两次;利伐沙班方案:15 mg每日两次×21天,随后20 mg每日一次,均治疗3个月。
  • 全因死亡阿哌沙班组1例(0.1%) vs 利伐沙班组4例(0.3%),相对风险0.25(95%CI 0.03–2.26),未达统计学显著。
  • 非出血或静脉血栓相关的严重不良事件阿哌沙班组36例(2.7%) vs 利伐沙班组30例(2.2%)。

适用人群与场景

  • 急性症状性肺栓塞或近端深静脉血栓患者,随机分配接受阿哌沙班或利伐沙班治疗3个月。

诊断标准与关键阈值

  • 主要终点为临床相关出血,即依据国际血栓与止血学会定义的大出血或临床相关非大出血复合终点,评估时间为3个月治疗期内。

处置流程与药物剂量

  • 阿哌沙班:10 mg每日两次,给药7天,随后5 mg每日两次,治疗3个月。
  • 利伐沙班:15 mg每日两次,给药21天,随后20 mg每日一次,治疗3个月。

研究设计与关键结果

  • 国际、前瞻性、随机、开放标签、盲法终点试验,2760例患者随机分配:阿哌沙班组1370例,利伐沙班组1390例。
  • 主要终点临床相关出血:阿哌沙班组44/1345例(3.3%) vs 利伐沙班组96/1355例(7.1%),相对风险0.46(95%CI 0.33–0.65;P<0.001)。
  • 全因死亡:阿哌沙班组1例(0.1%) vs 利伐沙班组4例(0.3%),相对风险0.25(95%CI 0.03–2.26)。
  • 非出血或静脉血栓相关的严重不良事件:阿哌沙班组36例(2.7%) vs 利伐沙班组30例(2.2%)。

证据类型、等级与局限

  • 证据类型:国际、前瞻性、随机、开放标签、盲法终点试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急性静脉血栓栓塞症患者3个月治疗期内,阿哌沙班较利伐沙班显著降低临床相关出血风险(3.3% vs 7.1%,相对风险0.46;95%CI 0.33–0.65;P<0.001)。

指南或共识出处

  • COBRRA试验(ClinicalTrials.gov注册号NCT03266783),由加拿大健康研究院等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications.

METHODS: In an international trial with a prospective, randomized, open-label, blinded end-point design, we assigned, in a 1:1 ratio, eligible patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis to receive apixaban or rivaroxaban for 3 months. Apixaban was given at a dose of 10 mg twice daily for 7 days followed by 5 mg twice daily, and rivaroxaban was given at a dose of 15 mg twice daily for 21 days followed by 20 mg daily. The primary outcome was clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, as defined according to the International Society on Thrombosis and Haemostasis, during the 3-month trial period. Secondary outcomes included death from any cause.

RESULTS: A total of 2760 patients underwent randomization: 1370 to the apixaban group and 1390 to the rivaroxaban group. A primary-outcome event occurred in 44 of 1345 patients (3.3%) in the apixaban group and 96 of 1355 patients (7.1%) in the rivaroxaban group (relative risk, 0.46; 95% confidence interval [CI], 0.33 to 0.65; P<0.001). Death from any cause occurred in 1 patient (0.1%) in the apixaban group and in 4 patients (0.3%) in the rivaroxaban group (relative risk, 0.25; 95% CI, 0.03 to 2.26). Serious adverse events unrelated to bleeding or venous thrombosis occurred in 36 patients (2.7%) in the apixaban group and in 30 patients (2.2%) in the rivaroxaban group.

CONCLUSIONS: Among patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. (Funded by the Canadian Institutes of Health Research and others; COBRRA ClinicalTrials.gov number, NCT03266783.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Castellucci LA, Chen VM, Kovacs MJ, et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026. PMID: 41812192. doi:10.1056/NEJMoa2510703

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。